Gemin X Pharmaceuticals to Present Data on Obatoclax at American Society of Hematology Annual Meeting

MALVERN, Pa. & MONTREAL, QC--(BUSINESS WIRE)--Dec 3, 2007 - Gemin X announced today that results of several clinical and preclinical studies of its lead anti-cancer candidate obatoclax (GX15-070) will be presented at the 49th annual meeting of the American Society of Hematology (ASH) in Atlanta, GA. Obatoclax is a novel, small molecule candidate in Phase 2 trials in multiple cancer indications that is specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.

"The presentation of multiple abstracts at ASH demonstrates the therapeutic promise of obatoclax and provides us with additional important information on the compound that will support its extensive clinical development program," said Dr. Gordon Shore, Chief Scientific Officer and Interim Chief Executive Officer of Gemin X. "These abstracts underscore obatoclax's potential synergistic effects in combination with other treatments, its utility in indications resistant to current therapies, its ability to initiate apoptosis, and its activity in a variety of cancer types. We believe that this emerging positive profile may position obatoclax as a potential new therapeutic that may improve treatment outcomes for cancer patients."

Details on the abstractsbeing presented at ASH:


Abstract Title:       Direct and Enhanced Cytotoxicity of the Bcl-2

                       Family Inhibitor GX15-070 on Rituximab-

                       Sensitive and Rituximab-Resistant B-NHL Clones.

                       Abstract No. 1402

Poster Session Info:  Lymphoma: Pre-Clinical: Chemotherapy and

                       Biologic Agents I, Board # 556-I

                      Saturday, December 8 5:30 PM


Abstract Title:       Bcl-2 Phosphorylation Modulates Sensitivity to

                       the BH3-Mimetic GX15-070 (Obatoclax) and

                       Reduces its Synergistic Interaction with

                       Bortezomib in Chronic Lymphocytic Leukemia

                       Cells. Abstract No. 3464

Poster Session Info:  Molecular Response Determinants, Board # 683-III

                      Monday, December 10 5:00 PM


Abstract Title:       GX15-070 and Bortezomib Induce Up-Regulation of

                       BH3 Single Domain Pro-Apoptotic Proteins Puma

                       and Noxa and is Associated with Synergistic

                       Anti-Tumor Activity in Rituximab-Sensitive,

                       Rituximab-Resistant Cell Lines (RSCL and RRCL),

                       and Primary Lymphoma Patient Specimens.

                       Abstract No. 1389

Poster Session Info:  Lymphoma: Pre-Clinical: Chemotherapy and

                       Biologic Agents I, Board # 543-I

                      Saturday, December 8 5:30 PM


Abstract Title:       Targeting 14-3-3 Sensitizes Native and Mutant

                       BCR-ABL to Inhibition with U0126, Rapamycin and

                       Bcl-2 Inhibitor GX15-070. Abstract No. 2920

Poster Session Info:  Chronic Myeloid Leukemia: Biology and

                       Pathophysiology II, Board #139-III

                      Monday, December 10 5:00 PM


Abstract Title:       A Phase 1 Trial of the Pan Bcl-2 Family

                       Inhibitor Obatoclax Mesylate (GX15-070) in

                       Combination with Bortezomib in Patients with

                       Relapsed/Refractory Mantle Cell Lymphoma:

                       Abstract No. 2569

Poster Session Info:  New Agents and Treatment Approaches in Non-

                       Hodgkin Lymphoma, Board #759-II

                      Sunday, December 9 6:00 PM


Abstract Title:       A Phase II Trial of the Small Molecule Pan-Bcl-2

                       Family Inhibitor Obatoclax Mesylate (GX15-070)

                       Administered by a 24-h Continuous Infusion

                       Every 2 Weeks to Patients with Chronic

                       Idiopathic Myelofibrosis (CIMF). Abstract No.

                       3553

Poster Session Info:  Myeloproliferative Syndromes: Therapy, Board

                       #772-III

                      Monday, December 10 5:00 PM


Abstract Title:       A Phase I Trial of the Small Molecule Pan-Bcl-2

                       Family Inhibitor Obatoclax Mesylate (GX15-070)

                       Administered by Continuous Infusion for up to

                       Four Days to Patients with Hematological

                       Malignancies. Abstract No. 892

Poster Session Info:  Acute Myeloid Leukemias: Therapy, Excluding

                       Transplantation I, Board #46-I

                      Saturday, December 8 5:30 PM


Abstract Title:       The BH3-Mimetic Obatoclax Restores the Response

                       to Dexamethasone in Glucocorticoid-Resistant

                       ALL through Induction of Autophagy. Abstract

                       No.806

Oral Session Info:    Simultaneous Session: Molecular Pharmacology:

                       Drug Resistance ,

                      Tuesday, December 11 7:45 AM

About Obatoclax

Obatoclax (GX15-070) is a small molecule indole bipyrrole drug compound that was discovered and is being developed at Gemin X. The attractive safety profile and mechanism of action of obatoclax offers the opportunity to treat many forms of cancer as both a single agent and in combination with current treatments. Obatoclax is currently being assessed in multiple Phase 2 company-sponsored clinical trials directed against multiple solid tumor and hematologic malignancies. In addition to clinical activity in multiple indications, obatoclax is generally well tolerated, and is without evidence of immuno- and myelosuppression.

About Gemin X

Gemin X Pharmaceuticals, Inc., through its subsidiary Gemin X Biotechnologies Inc., specializes in the discovery and development of target-based novel cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing GMX1777, a small molecule that targets cancer metabolism by a p53-independent mechanism. Gemin X is privately held and is located in Malvern, Pennsylvania and Montreal, Quebec. For additional information please visit Gemin X at www.geminx.com.

Contact

MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
or
Gemin X Biotechnologies Inc.
Diane Viens, 514-281-8989 ext.387
ir@geminx.com

Posted: December 2007

View comments

Hide
(web5)